Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
Apple Should Climb The Wall Of Worry
April 20, 2024
Microsoft Q3 Preview: Focusing On Copilot
April 19, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
LLY Stock News and Mentions of Eli Lilly and Company Stocktwits
Updated: April 23, 2024 (10:18)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Eli Lilly and Comp. Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Eli Lilly and Company (LLY).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Eli Lilly and Comp. stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Eli Lilly and Company (LLY)
April 23, 2024 (15:45) / "Benzinga" (by Benzinga Insights)
Market Whales and Their Recent Bets on LLY Options - Eli Lilly and Co ( NYSE:LLY )
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 54 trades. If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish ...
In Article Trend: Neutral
April 23, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (13:15) / "Motley Fool" (by George Budwell)
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment?
In Article Trend: Somewhat-Bullish
April 22, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Advances But Underperforms Market: Key Facts
Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
In Article Trend: Neutral
April 22, 2024 (18:21) / "Benzinga" (by Vandana Singh)
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma - Eli Lilly and Co ( NYSE:LLY )
On Monday, Eli Lilly and Company LLY agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. The deal terms were not disclosed.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:21) / "Benzinga" (by Vandana Singh)
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers' spending habits, particularly in the food industry.
In Article Trend: Somewhat-Bullish
April 20, 2024 (10:48) / "Motley Fool" (by David Jagielski)
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both.
In Article Trend: Somewhat-Bullish
April 19, 2024 (18:39) / "Investors Business Daily" (by Investor's Business Daily)
Even Medical Products Stocks Don't All Look Healthy In This Sick Market
Investors often turn to defensive types of stocks including medical companies in times of market turmoil, but even those can produce mixed results. Take IBD 50 medical products stocks such as Dexcom ( DXCM ) , which has wavered in a buy zone but ultimately slipped below its entry point.
In Article Trend: Neutral
April 19, 2024 (16:51) / "Investors Business Daily" (by IBD STAFF)
Stock Market Shows Bearish Action: Weekly Review
Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 19, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals - Eli Lilly and Co ( NYSE:LLY )
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:15) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
In Article Trend: Neutral
April 19, 2024 (12:30) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week
Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:50) / "Benzinga" (by Vandana Singh)
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 - Eli Lilly and Co ( NYSE:LLY )
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S's NVO Wegvoy ( ...
In Article Trend: Neutral
April 18, 2024 (14:33) / "Investors Business Daily" (by ALLISON GATLIN)
Could Eli Lilly's Sleep Apnea News Actually Help This CPAP Maker?
ResMed Stock Reverses Higher As Weight-Loss Drugs Seen Bolstering Its Devices Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly and Co LLY has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return of 23.13%. Currently, Eli Lilly and Co has a market capitalization of $711.81 billion.
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:53) / "Zacks Commentary" (by Zacks Equity Research)
April 18, 2024 (12:51) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly's ( LLY ) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
In Article Trend: Neutral
April 18, 2024 (09:10) / "Motley Fool" (by David Jagielski)
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
These stocks have taken different paths to where they are today, but both have been exceptional investments.
In Article Trend: Neutral
April 18, 2024 (08:20) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo
Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
April 17, 2024 (22:51) / "Motley Fool" (by Eric Volkman)
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
In Article Trend: Neutral
April 17, 2024 (18:01) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co's Options Frenzy: What You Need to Know - Eli Lilly and Co ( NYSE:LLY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 87 trades. If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:43) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Mixed Ahead Of Fed Data; Tesla Falls As Shareholder Votes Are Set, While Chip Leader Sinks
Stocks Mixed Ahead Of Fed Data. Tesla Falls As Shareholder Votes Are Set, While Chip Leader Sinks Investor's Business Daily ...
In Article Trend: Neutral
April 17, 2024 (12:59) / "Benzinga" (by Vandana Singh)
Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co ( NYSE:LLY )
Wednesday, Eli Lilly And Co LLY released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea ( OSA ) , a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep.
In Article Trend: Neutral
April 17, 2024 (12:57) / "Investors Business Daily" (by ALLISON GATLIN)
Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Study
Eli Lilly ( LLY ) stock popped Wednesday - and pushed shares of ResMed ( RMD ) lower - after its weight-loss drug reduced symptoms of sleep apnea in patients with obesity. Patients who received Lilly's tirzepatide on average had a 63% reduction in sleep apnea symptoms.
In Article Trend: Neutral
April 16, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
April 16, 2024 (18:25) / "Benzinga" (by Vandana Singh)
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades - Avalo Therapeutics ( NASDAQ:AVTX )
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa ( HS ) and additional updates.
In Article Trend: Somewhat-Bullish
April 16, 2024 (12:00) / "Investors Business Daily" (by Investor's Business Daily)
15 'Wealth Creator' Stocks Make Investors Filthy Rich
Not sure which S&P 500 stocks are the best to buy for the next 10 years? There's no question where the top place to put your money this past decade was. Fifteen S&P 500 stocks - including Apple ( AAPL ) , Microsoft ( MSFT ) and Alphabet ( GOOGL ) - are the top wealth creators in the past 10 ...
In Article Trend: Bullish
April 16, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Fidelity MSCI Health Care Index ETF ( FHLC ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:30) / "Motley Fool" (by George Budwell)
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:00) / "Motley Fool" (by George Budwell)
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares U.S. Pharmaceuticals ETF ( IHE ) ?
Sector ETF report for ...
In Article Trend: Neutral
April 13, 2024 (12:47) / "Motley Fool" (by David Jagielski)
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
In Article Trend: Somewhat-Bullish
April 13, 2024 (09:51) / "Motley Fool" (by Keith Speights)
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
You can own a basket of tremendously successful stocks with this ETF.
In Article Trend: Somewhat-Bullish
April 12, 2024 (23:00) / "Motley Fool" (by Eric Volkman)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market.
In Article Trend: Somewhat-Bullish
April 12, 2024 (17:22) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk ( NYSE:NVO )
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.
In Article Trend: Bullish
April 12, 2024 (15:54) / "Benzinga" (by Vandana Singh)
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy - Eli Lilly and Co ( NYSE:LLY )
U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co LLY cannot rely on state law to stop a compounding pharmacy, RXCompoundStore.com, from marketing its version of the drug tirzepatide. Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weightloss.
In Article Trend: Neutral
April 12, 2024 (14:40) / "Benzinga" (by Vandana Singh)
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee ( PRAC ) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists ( GLP-1 ) and suicidal or self-injurious thoughts and behaviors.
In Article Trend: Somewhat-Bearish
April 12, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Eli Lilly and Company ( LLY ) is a Trending Stock
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 11, 2024 (22:33) / "Motley Fool" (by Rich Smith)
Why Roche Holdings Stock Popped Today
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.
In Article Trend: Somewhat-Bullish
April 10, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Increases Despite Market Slip: Here's What You Need to Know
Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.
In Article Trend: Somewhat-Bullish
April 10, 2024 (19:23) / "Benzinga" (by Vandana Singh)
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies - Eli Lilly and Co ( NYSE:LLY ) , Amphastar Pharma ( NASDAQ:AMPH )
At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc AMPH highlighted why they remain excited about Baqsimi, the inhaled glucagon product for severe hypoglycemia. Amphastar Pharmaceuticals develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (02:32) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits' - NVIDIA ( NASDAQ:NVDA ) , Eli Lilly and Co ( NYSE:LLY )
Jim Cramer, CNBC's market commentator, recently shared his insights on Tuesday's market activity. He believes that stocks like NVIDIA Corp NVDA and Eli Lilly And Co LLY, which experienced a dip, still hold growth potential. What Happened: Cramer observed that despite the losses, these stocks have ...
In Article Trend: Neutral
April 9, 2024 (13:45) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co ( NYSE:LLY )
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
April 9, 2024 (11:02) / "Zacks Commentary" (by Zacks Equity Research)
Biophytis ( BPTS ) to Begin Phase II Obesity Study, Stock Up
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:35) / "Motley Fool" (by Adria Cimino)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue.
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term.
In Article Trend: Bullish
April 8, 2024 (19:34) / "Zacks Commentary" (by Neena Mishra)
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
We discuss attractive investment opportunities within the healthcare industry.
In Article Trend: Neutral
April 8, 2024 (15:43) / "Benzinga" (by The Bamboo Works)
ProfoundBio Discovers The Joys Of Having A Wealthy Owner - Genmab ( NASDAQ:GMAB ) , ArriVent BioPharma ( NASDAQ:AVBP )
Cancer treatment maker ProfoundBio announced it will be purchased by Denmark's Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
2 Growth Stocks to Buy Hand Over Fist in April
These healthcare companies' target markets substantially overlap.
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Market Edge Highlights: VICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly
ICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly are part of the Zacks Market Edge blog.
In Article Trend: Somewhat-Bullish
April 8, 2024 (10:30) / "Motley Fool" (by Adria Cimino)
This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market
Lilly's stock has climbed in the triple digits over the past 12 months.
In Article Trend: Somewhat-Bullish
April 8, 2024 (09:55) / "Motley Fool" (by Adria Cimino)
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news.
In Article Trend: Somewhat-Bullish
April 7, 2024 (14:00) / "CNBC" (by Paulina Likos)
Modelo maker Constellation Brands is primed for market share gains but we still see one issue with the company
Constellation Brands is positioned for market share gains with a strong business outlook despite this one overhang.
In Article Trend: Somewhat-Bullish
April 7, 2024 (11:15) / "Motley Fool" (by Alex Carchidi)
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
New findings could lead to more growth from their prized medicines.
In Article Trend: Somewhat-Bullish
April 6, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Things are going exactly as planned for the biotech giant.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk
Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Understanding Eli Lilly and Co's Position In Pharmaceuticals Industry Compared To Competitors - Eli Lilly and Co ( NYSE:LLY )
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (14:31) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co ( NYSE:LLY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 22 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish ...
In Article Trend: Neutral
April 4, 2024 (21:05) / "Zacks Commentary" (by Tracey Ryniec)
How to Create a Stock Portfolio that Pays $100 a Month
Forget buying a CD. Here's how to set yourself up with individual stocks that will net you passive income.
In Article Trend: Somewhat-Bullish
April 4, 2024 (08:55) / "Motley Fool" (by Adria Cimino)
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Viking shares have soared recently on optimism about its program.
In Article Trend: Somewhat-Bullish
April 3, 2024 (20:31) / "Motley Fool" (by Eric Volkman)
Why Eli Lilly Stock Topped the Market Today
One analyst following the company believes it could grow its revenue meaningfully this year.
In Article Trend: Somewhat-Bullish
April 3, 2024 (20:07) / "Benzinga" (by Neil Dennis)
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co ( NYSE:LLY ) , Amazon.com ( NASDAQ:AMZN )
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.
In Article Trend: Neutral
April 3, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Verve ( VERV ) Pauses Enrollment in Cholesterol Study, Stock Falls
Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.
In Article Trend: Neutral
April 3, 2024 (17:37) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S NVO has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic ( semaglutide ) will not be available in Germany during the second quarter.
In Article Trend: Neutral
April 3, 2024 (15:01) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co ( NYSE:LLY )
Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 41 unusual trades. Delving into the details, we found 26% of traders were bullish, while 73% showed bearish tendencies.
In Article Trend: Neutral
April 3, 2024 (12:09) / "Investors Business Daily" (by Investor's Business Daily)
Rally Holds Support; Five Stocks Eye Buy Points
Dow Jones Futures: Stock Market Rally Holds Support, Meta Near Buy Point. Tesla Skids Investor's Business Daily ...
In Article Trend: Neutral
April 3, 2024 (07:21) / "Benzinga" (by Benzinga Neuro)
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras - Costco Wholesale ( NASDAQ:COST ) , Eli Lilly and Co ( NYSE:LLY )
Costco Wholesale Corporation COST has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO.
In Article Trend: Somewhat-Bullish
April 2, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Eli Lilly (LLY) settling at $763.96, representing a +0.45% change from its previous close.
In Article Trend: Neutral
April 2, 2024 (20:53) / "Investors Business Daily" (by Investor's Business Daily)
Market Bends As Yields Jump; Tesla Skids As 5 Stocks Hang Tough
Dow Jones Futures: Market Slides But Holds Key Levels. Tesla Skids As Meta Eyes Buy Point Investor's Business Daily ...
In Article Trend: Neutral
April 2, 2024 (18:54) / "Benzinga" (by Vandana Singh)
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.
In Article Trend: Somewhat-Bullish
April 2, 2024 (18:41) / "Benzinga" (by Vandana Singh)
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand - Eli Lilly and Co ( NYSE:LLY )
Citi Research has increased the price target for Eli Lilly And Co LLY, reflecting increased anticipated risk-adjusted peak sales for the company's oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.
In Article Trend: Neutral
April 2, 2024 (16:19) / "Benzinga" (by Vandana Singh)
Why Is Verve Therapeutics Stock Trading Lower On Tuesday? - Verve Therapeutics ( NASDAQ:VERV )
Verve Therapeutics Inc VERV announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:09) / "Business Insider" (by Surbhi Jain)
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's ( NYSE:LLY ) strategic positioning and technical resilience present a compelling investment opportunity.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:08) / "CNBC" (by Morgan Chittum)
Jim Cramer says Microsoft's unbundling of Teams and Office is good news for this portfolio stock
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Neutral
April 2, 2024 (15:39) / "Benzinga" (by Surbhi Jain)
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience - Eli Lilly and Co ( NYSE:LLY )
Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's LLY strategic positioning and technical resilience present a compelling investment opportunity. Zepbound boasts impressive weight-loss efficacy in ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (11:45) / "Investors Business Daily" (by ED CARSON)
Ten Stocks Showing This Bullish Action, Including A Mag 7 Titan
Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (09:37) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson
Apple, NVIDIA, Eli Lilly, American Tower and McKesson are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
April 2, 2024 (09:10) / "Motley Fool" (by Adria Cimino)
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area.
In Article Trend: Somewhat-Bullish
April 1, 2024 (18:38) / "Zacks Commentary" (by Sheraz Mian)
Top Stock Reports for Apple, NVIDIA & Eli Lilly
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY).
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly and Company ( LLY ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:00) / "Motley Fool" (by Alex Carchidi)
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
All three companies have very long runways for growth ahead.
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:36) / "Investors Business Daily" (by ED CARSON)
Futures Rise In Reaction To 'Good' Inflation Data
Dow Jones Futures Rise After 'Good' Inflation Data. Nvidia AI Chip Peer Works On Base Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:30) / "Motley Fool" (by Prosper Junior Bakiny)
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations.
In Article Trend: Somewhat-Bullish
March 31, 2024 (13:45) / "Motley Fool" (by Rachel Warren)
Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond
Great companies in steadily growing industries can deliver enviable returns through the years.
In Article Trend: Somewhat-Bullish
March 30, 2024 (10:50) / "Motley Fool" (by and Prosper Junior Bakiny)
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects.
In Article Trend: Somewhat-Bullish
March 28, 2024 (20:50) / "Investors Business Daily" (by Investor's Business Daily)
Market Strong Before Inflation Data; Will Nvidia Peer Forge Base?
Market Strong Before Inflation Data. Will Nvidia Peer Forge Base? Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (17:55) / "Zacks Commentary" (by Andrew Rocco)
2 Top Biotech Buyout Candidates
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:52) / "Investors Business Daily" (by IBD STAFF)
Market Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally was mixed in a holiday-shortened week. The Nasdaq fell modestly while the Russell 2000 rose solidly. Many AI and other growth leaders suffered solid to sharp losses. DraftKings ( DKNG ) fell sharply as the NCAA moved to ban special prop bets following claims regarding a pro ...
In Article Trend: Neutral
March 28, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly and Co LLY has outperformed the market over the past 5 years by 30.75% on an annualized basis producing an average annual return of 43.59%. Currently, Eli Lilly and Co has a market capitalization of $741.67 billion.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:05) / "Motley Fool" (by David Jagielski)
Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?
Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:30) / "Motley Fool" (by Marc Rapport)
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators.
In Article Trend: Bullish
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 28, 2024 (12:00) / "Motley Fool" (by Prosper Junior Bakiny)
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:50) / "Motley Fool" (by Adria Cimino)
Prediction: This Will Be the Next "Magnificent Seven" Stock
This particular company's growth is set to take off...
In Article Trend: Somewhat-Bullish
March 27, 2024 (20:41) / "Investors Business Daily" (by Investor's Business Daily)
Futures: Small Caps Jump But Nvidia, Growth Leaders Retreat
Dow Jones Futures: Small Caps Power Higher While Nvidia, Growth Leaders Retreat Investor's Business Daily ...
In Article Trend: Neutral
March 27, 2024 (17:59) / "Benzinga" (by Neil Dennis)
US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar - Chevron ( NYSE:CVX ) , Eli Lilly and Co ( NYSE:LLY )
U.S. commodity exporters and pharmaceutical companies are among the top traders, with Japan casting a cautious eye toward the foreign exchange markets, in the coming days. Top exporters with significant Japanese interests include Exxon Mobil Corp XOM and Chevron Corp CVX.
In Article Trend: Neutral
March 27, 2024 (16:42) / "Zacks Commentary" (by Zacks Equity Research)
Viking ( VKTX ) Up 17% on Encouraging Oral Obesity Drug Data
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:22) / "Investors Business Daily" (by ALLISON GATLIN)
Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats
Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:23) / "Zacks Commentary" (by Zacks Equity Research)
Amazon ( AMZN ) Expands Same-Day Medication Delivery Service
Amazon (AMZN) expands same-day delivery of prescription medication to New York City and Los Angeles.
In Article Trend: Somewhat-Bullish
March 27, 2024 (13:46) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking - Eli Lilly and Co ( NYSE:LLY )
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 26, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 26, 2024 (17:56) / "Investors Business Daily" (by JAMES DETAR)
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (17:48) / "Benzinga" (by Vandana Singh)
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven ( NYSE:BHVN )
Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.
In Article Trend: Neutral
March 26, 2024 (15:23) / "CNBC" (by Jeff Marks)
Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:21) / "Zacks Commentary" (by Zacks Equity Research)
CHMP to Delay Nod on Biogen ( BIIB ) , Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
In Article Trend: Neutral
March 26, 2024 (14:21) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Awaits Consumer Confidence Data
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.
In Article Trend: Neutral
March 26, 2024 (13:02) / "Investors Business Daily" (by ALLISON GATLIN)
Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days
Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...
In Article Trend: Neutral
March 26, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In Article Trend: Bullish
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares U.S. Healthcare ETF ( IYH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (09:51) / "Motley Fool" (by Keith Speights)
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run.
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:33) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Set to Post Fifth Winning Month Amid Volatility
Wall Street is likely to record the fifth consecutive winning month despite volatility.
In Article Trend: Neutral
March 25, 2024 (11:13) / "Investors Business Daily" (by Investor's Business Daily)
Futures Fall With Market At Highs; 3 Stocks Near Buy Points
Dow Jones Futures Fall: Fed, AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (10:25) / "Motley Fool" (by Adam Spatacco)
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.
In Article Trend: Somewhat-Bullish
March 25, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Health Care Select Sector SPDR ETF ( XLV ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (07:55) / "Motley Fool" (by Joe Tenebruso)
The Best Stocks to Invest $10,000 in Right Now
These elite enterprises can help you grow richer.
In Article Trend: Bullish
March 24, 2024 (10:50) / "Motley Fool" (by Keith Speights)
59% of This Vanguard ETF Is Invested in the "Magnificent Seven" Stocks. Is It a No-Brainer Buy Right Now?
If you want to own all of the Magnificent Seven stocks plus other megacap winners, this ETF could be right up your alley.
In Article Trend: Bullish
March 22, 2024 (20:58) / "Investors Business Daily" (by Investor's Business Daily)
Two Tailwinds Continue To Fuel Market; 3 Stocks Setting Up Again
Dow Jones Futures: Dovish Fed, Nvidia-Led AI Boom Keep Driving Stock Market. 3 Stocks Near Buy Points Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry - Eli Lilly and Co ( NYSE:LLY )
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Eli Lilly and Co LLY and its primary competitors in the Pharmaceuticals industry.
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:34) / "Benzinga" (by Vandana Singh)
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.
In Article Trend: Neutral
March 22, 2024 (14:30) / "Motley Fool" (by Adam Spatacco)
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:30) / "Investors Business Daily" (by ADAM SHELL)
Learn How The Best Mutual Funds Deliver Benchmark-Beating Returns
Best Performing Mutual Funds Top Benchmarks Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (11:15) / "Motley Fool" (by Adam Spatacco)
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.
In Article Trend: Bullish
March 22, 2024 (08:55) / "Motley Fool" (by Adria Cimino)
Could Viking Therapeutics Become the Next Eli Lilly?
Viking shares have skyrocketed on its recent good news.
In Article Trend: Somewhat-Bullish
March 21, 2024 (19:09) / "Investors Business Daily" (by ALLISON GATLIN)
Medicare Will Cover Weight-Loss Drugs - For Some People
Weight-Loss Drugs Win Medicare Coverage. Here's What It Means For Novo Nordisk, Eli Lilly Investor's Business Daily ...
In Article Trend: Neutral
March 21, 2024 (17:23) / "Benzinga" (by Vandana Singh)
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health - Novo Nordisk ( NYSE:NVO )
In a significant development, Medicare may extend coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) to certain members with a history of heart disease.
In Article Trend: Neutral
March 20, 2024 (21:00) / "Benzinga" (by Neil Dennis)
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Eli Lilly and Co. LLY enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound - the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single ...
In Article Trend: Neutral
March 20, 2024 (17:21) / "Zacks Commentary" (by Zacks Equity Research)
Fusion ( FUSN ) Up 99% on $2.4B Buyout Offer From AstraZeneca
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (14:02) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co's Options Frenzy: What You Need to Know - Eli Lilly and Co ( NYSE:LLY )
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 20, 2024 (12:30) / "Motley Fool" (by David Jagielski)
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
The gap has been shrinking between these stocks over the past month.
In Article Trend: Neutral
March 20, 2024 (12:00) / "Investors Business Daily" (by MATT KRANTZ)
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss
Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.
In Article Trend: Somewhat-Bullish
March 20, 2024 (08:54) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics
Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.
In Article Trend: Neutral
March 19, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Surpasses Market Returns: Some Facts Worth Knowing
Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:58) / "Zacks Commentary" (by Andrew Rocco)
Time to be "Overweight" Viking Therapeutics
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
In Article Trend: Neutral
March 19, 2024 (13:55) / "Benzinga" (by Avi Kapoor)
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On' - Datadog ( NASDAQ:DDOG ) , Altimmune ( NASDAQ:ALT )
On CNBC's "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. MRVL reported a mixed quarter. "We got to wait," he added.
In Article Trend: Somewhat-Bullish
March 19, 2024 (13:03) / "Investors Business Daily" (by ALLISON GATLIN)
Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
Fusion Pharmaceuticals Scores $2 Billion AstraZeneca Takeover. Biotech Stock Nearly Doubles Investor's Business Daily ...
In Article Trend: Neutral
March 19, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly and Company ( LLY ) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:00) / "Forbes" (by Trefis Team)
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company's P/S ratio to ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:30) / "Motley Fool" (by Adam Spatacco)
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead.
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:26) / "Benzinga" (by Vandana Singh)
Why Is Fusion Pharmaceuticals Stock Trading Higher Today? - AstraZeneca ( NASDAQ:AZN ) , Fusion Pharmaceuticals ( NASDAQ:FUSN )
Tuesday, AstraZeneca Plc AZN agreed to acquire Fusion Pharmaceuticals Inc FUSN for $21.00 per share in cash plus a non-transferable contingent value right ( CVR ) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.
In Article Trend: Somewhat-Bullish
March 19, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Vanguard Health Care ETF ( VHT ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals.
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:21) / "Benzinga" (by Vandana Singh)
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly And Co's LLY much-in-demand weight-loss drug Zepbound ( tirzepatide ) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S's NVO rival obesity medicine Wegovy ( semglutide ) for the first time since its launch.
In Article Trend: Neutral
March 18, 2024 (06:00) / "Motley Fool" (by Alex Carchidi)
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
This company's growth story is about to get moving with gusto.
In Article Trend: Somewhat-Bullish
March 17, 2024 (13:00) / "Motley Fool" (by Keith Speights)
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
There's no need for delays in buying these great stocks.
In Article Trend: Neutral
March 17, 2024 (07:24) / "Motley Fool" (by Cory Renauer)
Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?
Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.
In Article Trend: Somewhat-Bullish
March 16, 2024 (18:00) / "Business Insider" (by Rick Orford)
The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone
There are only six trillion-dollar stocks worldwide, every one of which is a popular name. And they all rightfully sit at the top of their sectors. There's a certain allure to reaching $1 trillion, and investors are always looking for the next one to breach that valuation.
In Article Trend: Somewhat-Bullish
March 16, 2024 (13:15) / "Motley Fool" (by Alex Carchidi)
Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?
The drugmaker is caught up in an unexpected situation with regulators.
In Article Trend: Neutral
March 16, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Eli Lilly Partners With Amazon's Pharmacy Business: Here's Why Both Stocks Should Win From the Deal
The world's biggest drugmaker has joined forces with the world's biggest online pharmacy provider.
In Article Trend: Somewhat-Bullish
March 15, 2024 (19:00) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 20 Years - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly and Co LLY has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 12.84%. Currently, Eli Lilly and Co has a market capitalization of $713.27 billion.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:44) / "Investors Business Daily" (by KEN SHREVE)
Nasdaq, S&P 500 Extend Losses; Adobe Sell-Off Casts Pall On Tech; Ulta Beauty Tumbles
Nasdaq, S&P 500 Extend Losses. Adobe Sell-Off Casts Pall On Tech. Ulta Beauty Tumbles Investor's Business Daily ...
In Article Trend: Neutral
March 15, 2024 (13:19) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:15) / "Motley Fool" (by David Jagielski)
Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.
The company's valuation may be high but that doesn't mean Eli Lilly is anywhere near its peak.
In Article Trend: Somewhat-Bullish
March 15, 2024 (11:46) / "Motley Fool" (by Justin Pope)
Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"
Tesla is failing to keep pace with the rest of the Magnificent Seven.
In Article Trend: Somewhat-Bullish
March 15, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
In Article Trend: Neutral
March 14, 2024 (20:03) / "Benzinga" (by Vandana Singh)
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca ( NASDAQ:AZN ) , Johnson & Johnson ( NYSE:JNJ )
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.
In Article Trend: Neutral
March 14, 2024 (15:50) / "Zacks Commentary" (by Zacks Equity Research)
Amazon ( AMZN ) Boosts Pharmacy Efforts With Lilly's Partnership
Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Partners Amazon to Deliver Drugs Like Zepbound
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
In Article Trend: Somewhat-Bullish
March 14, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
Should Investors Worry About Eli Lilly's Latest Regulatory Setback?
There are good reasons to remain optimistic.
In Article Trend: Somewhat-Bullish
March 13, 2024 (23:00) / "CNBC" (by Anna Gleason)
Experts hesitate on weight loss ETFs amid the obesity drug boom
While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.
In Article Trend: Neutral
March 13, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Ascends While Market Falls: Some Facts to Note
Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:19) / "Investors Business Daily" (by Investor's Business Daily)
Lilly Teams Up With Amazon To Deliver Weight-Loss Drug
Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...
In Article Trend: Neutral
March 13, 2024 (16:35) / "Benzinga" (by Piero Cingari)
Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs - Agilent Technologies ( NYSE:A ) , Avantor ( NYSE:AVTR )
Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:04) / "Investors Business Daily" (by ALLISON GATLIN)
IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity
Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...
In Article Trend: Neutral
March 13, 2024 (14:31) / "Benzinga" (by Vandana Singh)
Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs - Novo Nordisk ( NYSE:NVO )
As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has intensified.
In Article Trend: Neutral
March 13, 2024 (13:45) / "Motley Fool" (by Prosper Junior Bakiny)
March 13, 2024 (12:41) / "Benzinga" (by Vandana Singh)
Obesity Drugs On Amazon - Eli Lilly Partners With Amazon's Pharmacy Unit To Deliver Drug Prescriptions, Including Popular Zepbound For Weight Loss - Eli Lilly and Co ( NYSE:LLY )
Amazon.com's AMZN Amazon Pharmacy has integrated Eli Lilly And Co's LLY LillyDirect into its services, enabling home delivery of select medications for diabetes, obesity, and migraine.
In Article Trend: Neutral
March 13, 2024 (09:03) / "Motley Fool" (by Adria Cimino)
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking aims to enter a market that may be worth $100 billion in a few years.
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:25) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Says Tuesday Rally Was Driven By Nvidia, Eli Lilly And Other 'Stocks Reacting Positively To Good Earnings Per Share News' - Costco Wholesale ( NASDAQ:COST ) , Broadcom ( NASDAQ:AVGO )
U.S. stocks experienced a rise on Tuesday following consecutive losses for the S&P 500 and Nasdaq. What Happened: This positive turn occurred despite a slightly warmer-than-expected February consumer price index.
In Article Trend: Somewhat-Bullish
March 12, 2024 (18:48) / "Benzinga" (by Vandana Singh)
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers - AnaptysBio ( NASDAQ:ANAB )
Monday, AnaptysBio Inc ANAB reported a fourth-quarter 2023 EPS of $ ( 1.59 ) , slightly better than the consensus of $ ( 1.60 ) . The company reported sales of $9.01 million, surpassing the consensus of $2.23 million.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:01) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co ( NYSE:LLY )
Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 19 unusual trades. Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies.
In Article Trend: Neutral
March 12, 2024 (11:45) / "Motley Fool" (by Alex Carchidi)
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way.
In Article Trend: Somewhat-Bullish
March 12, 2024 (09:21) / "Motley Fool" (by Sean Williams)
Meet the Unknown Small-Cap Company That's Been Paying a Dividend for at Least 66 Years Longer Than Coca-Cola, ExxonMobil, and Eli Lilly
A relatively tiny company ($508 million market cap) that most investors have never heard of has been doling out a consecutive dividend for over two centuries -- including 104 years longer than Coca-Cola!
In Article Trend: Somewhat-Bullish
March 12, 2024 (05:09) / "Benzinga" (by Ananya Gairola)
Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic - 'Shame, Blame And The Weight Loss Revolution' - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey's upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs.
In Article Trend: Neutral
March 11, 2024 (19:01) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Eli Lilly and Co's Latest Options Trends - Eli Lilly and Co ( NYSE:LLY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly and Co. Looking at options history for Eli Lilly and Co LLY we detected 128 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish ...
In Article Trend: Neutral
March 11, 2024 (14:14) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly
Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
March 11, 2024 (10:59) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk's ( NVO ) Wegovy Gets FDA Nod to Reduce Heart Risk
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
In Article Trend: Neutral
March 11, 2024 (10:34) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Stock Down as FDA Delays Decision on Donanemab
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
In Article Trend: Neutral
March 10, 2024 (20:00) / "PR Newswire" (by Eli Lilly and Company)
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its ... PR ...
In Article Trend: Somewhat-Bullish
March 10, 2024 (13:29) / "Motley Fool" (by Keith Speights)
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does.
In Article Trend: Somewhat-Bullish
March 10, 2024 (10:05) / "Motley Fool" (by Daniel Foelber)
Meet the 5 Stocks That Have Contributed Almost All of the S&P 500's 2024 Gains
These companies have contributed the lion's share of the S&P 500's 7% year-to-date gain.
In Article Trend: Somewhat-Bullish
March 10, 2024 (08:33) / "Motley Fool" (by Cory Renauer)
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights.
In Article Trend: Somewhat-Bullish
March 9, 2024 (15:00) / "Motley Fool" (by Joe Tenebruso)
The Best Stocks to Invest $50,000 in Right Now
These stalwart companies can help you grow your wealth.
In Article Trend: Bullish
March 9, 2024 (10:07) / "Motley Fool" (by Adria Cimino)
Is Eli Lilly the Best Pharmaceutical Stock for You?
Lilly's recently approved weight-loss drug is off to a good start.
In Article Trend: Somewhat-Bullish
March 9, 2024 (03:16) / "Motley Fool" (by Eric Volkman)
Why Eli Lilly Stock Flopped on Friday
An important new drug's potential approval has been pushed back, and the timing is unclear.
In Article Trend: Neutral
March 8, 2024 (21:59) / "Benzinga" (by Chris Katje)
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies - Or Could They Get Another Lift? - Eli Lilly and Co ( NYSE:LLY ) , Walt Disney ( NYSE:DIS )
Legendary television mogul Oprah Winfrey recently announced she was stepping down from the board of directors of WeightWatchers. The announcement, along with fourth-quarter financial results, sent shares of WeightWatchers parent WW International WW lower last month.
In Article Trend: Neutral
March 8, 2024 (19:31) / "Investors Business Daily" (by Investor's Business Daily)
Novo's Weight-Loss Blockbuster Wins Another Approval
Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...
In Article Trend: Neutral
March 8, 2024 (16:23) / "CNN" (by Anna Cooban)
Ozempic or Tesla? Markets are in no doubt which is hotter | Business
Ozempic or Tesla? Markets are in no doubt which is hotter ...
In Article Trend: Neutral
March 8, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
S&P 500 Soars to New Highs: 5 Best Stocks YTD
The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.
In Article Trend: Somewhat-Bullish
March 8, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry - Eli Lilly and Co ( NYSE:LLY )
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Eli Lilly and Co LLY against its key competitors in the ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:59) / "Money Morning" (by Chris Johnson)
This is Just the Beginning of Mind Medicine
My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:58) / "Investors Business Daily" (by IBD STAFF)
Market Rally Hits Fresh Highs As Nvidia, Bitcoin Soar: Weekly Review
The stock market rally suffered a sharp loss Tuesday but quickly rebounded, with the S&P 500 and Nasdaq composite hitting record highs. The Dow Jones fell modestly, but pared losses. Nvidia ( NVDA ) and chipmakers led the advance, while some software names struggled.
In Article Trend: Neutral
March 8, 2024 (15:05) / "Zacks Commentary" (by Sweta Killa)
S&P 500 Soars to New Highs: 5 Best Stocks YTD
The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:03) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Up on Upbeat Data From New Obesity Pill Study
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Eli Lilly and Company ( LLY ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:08) / "Investors Business Daily" (by Investor's Business Daily)
FDA Delays Decision On Eli Lilly's Alzheimer Drug
The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:45) / "PR Newswire" (by Eli Lilly and Company)
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 ... PR ...
In Article Trend: Neutral
March 8, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the VanEck Pharmaceutical ETF ( PPH ) ?
Sector ETF report for PPH ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:00) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Market Edge Highlights: NVDA, DELL, LLY, CMG and CAVA
NVDA, DELL, LLY, CMG and CAVA have been highlighted in this Market Edge article.
In Article Trend: Somewhat-Bullish
March 8, 2024 (05:22) / "Benzinga" (by Benzinga Neuro)
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan - Alphabet ( NASDAQ:GOOG ) , Apple ( NASDAQ:AAPL )
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan.
In Article Trend: Neutral
March 7, 2024 (19:47) / "Benzinga" (by Vandana Singh)
Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly And Co LLY revealed on Thursday that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.
In Article Trend: Neutral
March 7, 2024 (18:18) / "Benzinga" (by Vandana Singh)
Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending - Cigna Group ( NYSE:CI )
Thursday, Evernorth Health Services, a subsidiary of Cigna Group CI introduced a financial guarantee within its EncircleRx program. The move aims to provide clients with predictability when covering GLP-1s, ultimately empowering companies and health plans to exercise better control over their ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Up 7.5% Since Last Earnings Report: Can It Continue?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 7, 2024 (15:33) / "Zacks Commentary" (by Tracey Ryniec)
Should You Buy Red-Hot Stocks Now or Wait?
After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?
In Article Trend: Neutral
March 7, 2024 (13:00) / "Benzinga" (by PRNewswire)
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care - Eli Lilly and Co ( NYSE:LLY )
Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company LLY today launched the next phase of its Get Better corporate branding campaign with a new focus on ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:46) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data Why Novo Nordisk Stock Is Trading Higher Today - Novo Nordisk ( NYSE:NVO )
Thursday, Novo Nordisk A/S NVO is holding its Capital Markets Day. Its executive management and other members of senior management will provide a full review of strategy, operations, and financial targets.
In Article Trend: Neutral
March 7, 2024 (11:44) / "Investors Business Daily" (by ED CARSON)
Novo Nordisk Jumps On Strong Results For New Obesity Drug
Novo Nordisk ( NVO ) said early Thursday that its experimental oral drug amycretin showed a 13.1% weight loss in participants after 12 weeks in a phase 1 trial. Shares of the Danish drug giant jumped, while rival Eli Lilly ( LLY ) fell.
In Article Trend: Somewhat-Bullish
March 6, 2024 (23:41) / "Motley Fool" (by Eric Volkman)
Why Meta Platforms Stock Topped the Market Today
Investors were happy that the company had a generally uneventful Wednesday.
In Article Trend: Somewhat-Bullish
March 6, 2024 (17:33) / "Zacks Commentary" (by Zacks Equity Research)
Nektar ( NKTR ) Begins Phase IIb Study Rezpeg in Alopecia Areata
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
In Article Trend: Neutral
March 6, 2024 (15:25) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom Pops As It Enters A New CGM Market: Non-Diabetics
Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:33) / "Benzinga" (by Vandana Singh)
What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and "finishing" of its injector pens.
In Article Trend: Neutral
March 6, 2024 (10:50) / "Motley Fool" (by Keith Speights)
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:40) / "Investors Business Daily" (by ALLISON GATLIN)
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...
In Article Trend: Neutral
March 5, 2024 (14:53) / "Motley Fool" (by Adam Spatacco)
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:15) / "Motley Fool" (by Alex Carchidi)
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender.
In Article Trend: Neutral
March 5, 2024 (06:33) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' - NVIDIA ( NASDAQ:NVDA ) , Eli Lilly and Co ( NYSE:LLY )
CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip.
In Article Trend: Somewhat-Bullish
March 4, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.
In Article Trend: Somewhat-Bullish
March 4, 2024 (18:32) / "MarketWatch" (by Joseph Adinolfi)
Two more stock indexes are on track for records: What that means for the bull market
Both the S&P 400 midcap Index and an ETF that tracks the S&P 500 equal-weight index appeared poised for record closes on Monday, an indication that more stocks are joining a rally that has been criticized for its dependence on Big Tech.
In Article Trend: Neutral
March 4, 2024 (16:02) / "Benzinga" (by Benzinga Insights)
Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co ( NYSE:LLY )
Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 80 unusual trades. Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies.
In Article Trend: Neutral
March 4, 2024 (11:25) / "Motley Fool" (by Rich Smith)
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?
There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer.
In Article Trend: Neutral
March 4, 2024 (10:48) / "Motley Fool" (by Keith Speights)
Here's How Much You'd Have If You Invested $10,000 in Eli Lilly Stock When Billionaire George Soros First Bought It
The tricky part would have been to not sell the pharmaceutical giant's shares when Soros did.
In Article Trend: Somewhat-Bullish
March 4, 2024 (09:55) / "Motley Fool" (by James Brumley)
This Is the Biggest Company Not in the "Magnificent Seven" -- but It Deserves to Be
It's in a distinctly different business than the "Magnificent Seven" companies, but it deserves the same attention.
In Article Trend: Somewhat-Bullish
March 3, 2024 (17:51) / "Motley Fool" (by Alex Carchidi)
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds.
In Article Trend: Somewhat-Bullish
March 3, 2024 (14:35) / "Motley Fool" (by Prosper Junior Bakiny)
Better Buy: Eli Lilly vs. Viking Therapeutics
These two biotechs could eventually go head to head in a fast-growing market.
In Article Trend: Somewhat-Bullish
March 2, 2024 (14:30) / "Motley Fool" (by and Prosper Junior Bakiny)
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
In Article Trend: Somewhat-Bullish
March 2, 2024 (13:15) / "Motley Fool" (by Adam Spatacco)
Is It Too Late to Buy Eli Lilly Stock Now?
Eli Lilly stock is having a moment, but the company could easily continue soaring.
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:53) / "Investors Business Daily" (by ED CARSON)
Market Rally At Highs; Here's What To Do Now
Dow Jones Futures: Nasdaq Hits Record High, Taiwan Semi Jumps. Here's What To Do Now Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:05) / "Benzinga" (by Piero Cingari)
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla - SPDR S&P 500 ( ARCA:SPY )
The U.S. stock market continues its unchallenged bull run, with Wall Street notching yet another week of record-breaking highs for the S&P 500 and Nasdaq 100 indices. This ongoing surge demonstrates the remarkable strength of the bullish sentiment, with stocks marking their 16th positive week out ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (20:44) / "Benzinga" (by Vandana Singh)
Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co ( NYSE:LLY )
BofA Securities says Eli Lilly and Company LLY remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% ( compared to the DRG index's +10% ) .
In Article Trend: Bullish
March 1, 2024 (17:52) / "MarketWatch" (by Philip van Doorn)
How investors can ride along as a global commodity market shifts away from China
China has long dominated the world market for rare earth minerals, which are required components of many devices.
In Article Trend: Neutral
March 1, 2024 (17:11) / "Investors Business Daily" (by IBD STAFF)
Rally At Highs After Big Earnings, Inflation Data: Weekly Review
Market Rally At High: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
March 1, 2024 (16:42) / "CNBC" (by Morgan Chittum)
An analyst call on red-hot Broadcom indicates a possible buying opportunity ahead
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales
Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...
In Article Trend: Neutral
March 1, 2024 (13:45) / "Motley Fool" (by David Jagielski)
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:00) / "Motley Fool" (by Marc Rapport)
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:31) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (06:59) / "Motley Fool" (by Alex Carchidi)
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable.
In Article Trend: Somewhat-Bullish
March 1, 2024 (06:07) / "Benzinga" (by Benzinga Neuro)
Ozempic, Wegovy And Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
The World Health Organization ( WHO ) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone.
In Article Trend: Neutral
February 29, 2024 (14:00) / "Motley Fool" (by Prosper Junior Bakiny)
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
These stocks meet many of the criteria long-term investors look for.
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:55) / "MarketWatch" (by Ciara Linnane)
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
Viking Therapeutics has a stock offering starting at $85 - a discount from its Wednesday closing price of $94.50.
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:45) / "Motley Fool" (by George Budwell)
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week.
In Article Trend: Neutral
February 29, 2024 (11:42) / "Motley Fool" (by Adria Cimino)
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
Viking stock surged in the triple digits in one trading session.
In Article Trend: Neutral
February 29, 2024 (09:53) / "Motley Fool" (by Cory Renauer)
Is Viking Therapeutics a Buy Now?
The stock recently jumped more than 100% overnight thanks to surprising results from its anti-obesity candidate.
In Article Trend: Somewhat-Bullish
February 28, 2024 (22:30) / "MarketWatch" (by Bill Peters)
Oprah's departure from Weight Watchers' board is the latest bad news for the stock, amid weight-loss-drug frenzy
Shares of WW International Inc., better known as Weight Watchers, tumbled after hours on Wednesday, as the weight-loss platform said Oprah Winfrey planned to leave its board and donate her stake in the company after revealing that she used a weight-loss drug.
In Article Trend: Neutral
February 28, 2024 (17:05) / "Benzinga" (by Vandana Singh)
Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say - Viking Therapeutics ( NASDAQ:VKTX )
Viking Therapeutics Inc VKTX recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo. The San Diego-based company also announced a capital raise of $350 ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (16:29) / "CNBC" (by Morgan Chittum)
One down one to go - what we learned from TJX's great quarter and hope to hear from Salesforce
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Neutral
February 28, 2024 (16:18) / "MarketWatch" (by Ciara Linnane)
Viking Therapeutics' weight-loss drug data makes company takeover target
Viking Therapeutics Inc.'s stock rose another 8% Wednesday to extend its week-to-date gains to 145%, as analysts weighed in on its positive weight-loss drug news with some bullish commentary and said the company has become an attractive takeover target.
In Article Trend: Neutral
February 28, 2024 (15:46) / "Benzinga" (by Vandana Singh)
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss - Eli Lilly and Co ( NYSE:LLY ) , Bristol-Myers Squibb ( NYSE:BMY )
Eli Lilly And Co's LLY CEO, David Ricks, shared the pharmaceutical giant's plans to introduce its obesity drug, tirzepatide, in India as early as next year. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.
In Article Trend: Somewhat-Bullish
February 28, 2024 (14:12) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
February 28, 2024 (08:59) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Weighs In On Palo Alto, Eli Lilly And Salesforce, Says Price Target Bump For This Stock A 'Red Flag' - Eli Lilly and Co ( NYSE:LLY ) , Salesforce ( NYSE:CRM )
During Tuesday's CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer emphasizing heightened threats following a recent breach at UnitedHealth.
In Article Trend: Neutral
February 27, 2024 (23:01) / "Motley Fool" (by Eric Volkman)
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long.
In Article Trend: Neutral
February 27, 2024 (21:07) / "Kiplinger" (by Karee Venema)
Stock Market Today: Stocks End Mixed After Disappointing Economic Data
Tuesday marked another choppy day for stocks as investors looked ahead to this week's key inflation update and the impact it may or may not have on the Fed's plans for interest rates.
In Article Trend: Neutral
February 27, 2024 (20:35) / "Benzinga" (by Neil Dennis)
Nvidia, Eli Lilly, AMD Enjoy High Equity Valuations: Do Higher Rates Put Them In Peril? - Advanced Micro Devices ( NASDAQ:AMD ) , Eli Lilly and Co ( NYSE:LLY )
Higher long-term rates typically matter a lot to equity valuations. However, according to DataTrek, today's mega-cap stocks are likely to weather the current higher rate environment. Nvidia Corporation NVDA has a price-to-earnings ( P/E ) ratio of 65.8 Eli Lilly And Company LLY even higher ...
In Article Trend: Neutral
February 27, 2024 (19:28) / "Investors Business Daily" (by Investor's Business Daily)
How Beam, Up 28% Today, Is Planning To Take On Crispr
Beam Stock Rockets To Year High As Efforts To Take On Crispr Deepen Investor's Business Daily ...
In Article Trend: Neutral
February 27, 2024 (16:39) / "Zacks Commentary" (by Mark Vickery)
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
In Article Trend: Somewhat-Bullish
February 27, 2024 (12:58) / "Investors Business Daily" (by Investor's Business Daily)
Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results
Viking Therapeutics ( VKTX ) said Tuesday that its weight-loss drug achieved all goals of its phase two study. Viking stock more than doubled in premarket trade. Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , which already have weight-loss drugs on the market, fell modestly.
In Article Trend: Neutral
February 27, 2024 (12:22) / "MarketWatch" (by Ciara Linnane)
Viking Therapeutics' stock doubles after company reports positive results in trial of weight-loss drug
Investors cheer what may be a cheap way to play the current weight-loss drug mania.
In Article Trend: Neutral
February 27, 2024 (04:05) / "Benzinga" (by Benzinga Neuro)
Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer - Broadcom ( NASDAQ:AVGO ) , Eli Lilly and Co ( NYSE:LLY )
CNBC's Jim Cramer has identified three companies that could potentially join the trillion-dollar club, in the wake of Nvidia Corp's NVDA rapid ascension. What Happened: On Monday, Cramer named Eli Lilly and Co LLY, Berkshire Hathaway Inc BRK BRK, and Tesla Inc TSLA as potential candidates for the ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (00:51) / "MarketWatch" (by Bill Peters)
Hims & Hers' stock jumps on hopes of a first profitable year, as it floats opportunities in weight loss
Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations.
In Article Trend: Somewhat-Bullish
February 26, 2024 (18:32) / "Investors Business Daily" (by KIMBERLEY KOENIG)
Another Reason Why Nvidia Is King Of Tech
Nvidia Stock: Another Reason Why It's The King Of Tech Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 26, 2024 (18:25) / "Benzinga" (by Vandana Singh)
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen ( NASDAQ:AMGN )
Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...
In Article Trend: Neutral
February 26, 2024 (16:31) / "Benzinga" (by Neil Dennis)
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors - AstraZeneca ( NASDAQ:AZN ) , Catalent ( NYSE:CTLT )
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company's shares 30% higher.
In Article Trend: Somewhat-Bullish
February 26, 2024 (15:52) / "Investors Business Daily" (by Investor's Business Daily)
Biotech Stocks In A Tizzy As New Weight-Loss Rival Enters The Arena
Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 26, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Eli Lilly and Company ( LLY ) is a Trending Stock
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
February 26, 2024 (12:30) / "Investors Business Daily" (by ED CARSON)
Warren Buffett's Berkshire Is On Cusp Of Joining The $1 Trillion Club
The trillion-dollar club is largely the preserve of tech titans such as Apple ( AAPL ) and Nvidia ( NVDA ) , with Meta Platforms ( META ) rejoining that level this year. But Warren Buffett's Berkshire Hathaway ( BRKB ) is knocking on the door. Berkshire Hathaway has a $952.75 billion ...
In Article Trend: Neutral
February 24, 2024 (12:04) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors.
In Article Trend: Somewhat-Bullish
February 24, 2024 (11:00) / "Motley Fool" (by Motley Fool Staff)
Harvard Business Professor on Failing Well
Why would Eli Lilly put on a failure party?
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website